Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

JTO clinical and research reports·2026
Same author

Endomyocardial Biopsy in Suspected Immune Checkpoint Inhibitor-Myocarditis: Histologic Spectrum and Correlations With Clinical and Cardiac Magnetic Resonance Features.

Journal of the American Heart Association·2026
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

High-Throughput Geocoding to Assess Short-Term Air Pollution in Correlation With Mortality in a French Cancer Patient Cohort.

International journal of cancer·2026
Same author

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

Cancer medicine·2026
Same author

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Oncology and therapy·2026

Related Experiment Video

Updated: May 22, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Chemotherapy and targeted agents for thymic malignancies.

Nicolas Girard1

  • 1Department of Respiratory Medicine, Pilot Unit for the Management of Rare Intrathoracic Tumors, National Expert Center for Thymic Malignancies, Louis Pradel Hospital, Hospices Civils de Lyon, Avenue Doyen Lépine, Lyon, France. nicolas.girard@chu-lyon.fr.

Expert Review of Anticancer Therapy
|May 19, 2012
PubMed
Summary

Thymic malignancies, rare aggressive tumors, are often treated with surgery or chemotherapy. Molecular insights are paving the way for personalized medicine approaches in treating these challenging thymic cancers.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Genetics

Background:

  • Thymic malignancies are rare, aggressive epithelial tumors.
  • Thymomas typically occur in the anterior mediastinum and are often resectable.
  • Locally advanced, metastatic, or recurrent disease may require chemotherapy, surgery, or radiotherapy.

Purpose of the Study:

  • To review the current treatment strategies for thymic malignancies.
  • To highlight the role of chemotherapy in managing advanced or recurrent thymic tumors.
  • To discuss the emerging potential of personalized medicine based on molecular characterization.

Main Methods:

  • Literature review of thymic malignancy treatment.
  • Analysis of chemotherapy's role in neoadjuvant, adjuvant, and metastatic settings.
  • Exploration of recent molecular findings in thymoma and thymic carcinoma.

Main Results:

  • Upfront surgical resection is common for localized thymomas.
  • Chemotherapy is a key modality for locally advanced, metastatic, and recurrent thymic malignancies.
  • Molecular profiling is identifying novel therapeutic targets.

Conclusions:

  • Multimodality treatment is essential for thymic malignancies.
  • Personalized medicine holds promise for future therapeutic advancements.
  • Continued research into molecular targets is crucial for improving patient outcomes.